GE HealthCare Technologies (GEHC) Morgan Stanley 22nd Annual Global Healthcare Conference summary

Key takeaways from public company transition

• Imaging has become indispensable for device and drug precision, driving growth.

• AI integration in radiology devices is accelerating, with over 70 FDA-approved devices.

• Execution focus and lean culture have enabled margin improvements and operational transformation.

• Radiopharmaceuticals are a major area of growth, with expanding disease state applications.

Market and service trends

• Service business is a key asset, with high contract attachment rates for advanced equipment.

• Growth in sophisticated modalities like MRI and PET CT supports service expansion.

• Higher-end products globally see better service attachment, especially with advanced software.

• Installation and upgrade costs influence modality choices, with AI enhancing lower-cost systems.

AI strategy and customer alignment

• AI is deployed at device, departmental, and enterprise levels, with current value in device optimization.

• AI improves workflow, image quality, and diagnostic accuracy, reducing exam times.

• Cloud-based SaaS models are emerging, enabling OpEx-based services and customer stickiness.

• Value creation focuses on patient outcomes, customer ROI, and productivity, not just technology.